Aquestive Therapeutics (AQST) Stock Price, News & Analysis

Company Overview

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Key Stats

• Today's Range: $4.44 to $4.69
• 50-Day Range: $4.44 to $5.66
• 52-Week Range: $1.84 to $6.23
• Volume: 1.12 million shs
• Average Volume: 1.75 million shs
• Market Capitalization: $415.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.80
• Consensus Rating: Buy

Aquestive Therapeutics Stock Analysis - MarketRank™

Aquestive Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 643rd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Aquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aquestive Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Aquestive Therapeutics are expected to decrease in the coming year, from ($0.47) to ($0.54) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aquestive Therapeutics is -10.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aquestive Therapeutics is -10.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.12% of the outstanding shares of Aquestive Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Aquestive Therapeutics has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Aquestive Therapeutics has recently decreased by 6.02%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aquestive Therapeutics does not currently pay a dividend.

Dividend Growth

Aquestive Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.12% of the outstanding shares of Aquestive Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Aquestive Therapeutics has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Aquestive Therapeutics has recently decreased by 6.02%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.49

News Sentiment

Aquestive Therapeutics has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Aquestive Therapeutics this week, compared to 3 articles on an average week.

Search Interest

16 people have searched for AQST on MarketBeat in the last 30 days. This is an increase of 78% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aquestive Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.85% of the stock of Aquestive Therapeutics is held by insiders.

Percentage Held by Institutions

Only 32.45% of the stock of Aquestive Therapeutics is held by institutions.

AQST Stock Analysis - Frequently Asked Questions

How have AQST shares performed this year?

Aquestive Therapeutics' stock was trading at $2.02 on January 1st, 2024. Since then, AQST shares have increased by 125.5% and is now trading at $4.5550.
View the best growth stocks for 2024 here.

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced its earnings results on Monday, November, 4th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.01. The business had revenue of $13.54 million for the quarter, compared to analyst estimates of $12.69 million.

When did Aquestive Therapeutics IPO?

Aquestive Therapeutics (AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

Who are Aquestive Therapeutics' major shareholders?

Aquestive Therapeutics' top institutional shareholders include Geode Capital Management LLC (1.83%), State Street Corp (1.64%), Janney Montgomery Scott LLC (1.01%) and Charles Schwab Investment Management Inc. (0.22%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, Peter E Boyd and Lori J Braender.
View institutional ownership trends.

How do I buy shares of Aquestive Therapeutics?

Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aquestive Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and General Electric (GE).

Company Calendar

• Last Earnings: 11/04/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/04/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AQST
• CUSIP: N/A
• CIK: 1398733
• Web: www.aquestive.com
• Phone: (908) 941-1900
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.80
• High Stock Price Target: $13.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +115.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,870,000.00
• Net Margins: -59.75%
• Pretax Margin: -59.58%
• Return on Equity: N/A
• Return on Assets: -33.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.37
• Quick Ratio: 5.91

Sales & Book Value

• Annual Sales: $50.58 million
• Price / Sales: 8.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.50) per share
• Price / Book: -9.11

Miscellaneous

• Outstanding Shares: 91,180,000
• Free Float: 84,021,000
• Market Cap: $415.32 million
• Optionable: Optionable
• Beta: 2.82